



= d que 126

L2

STR



Page 1-A



Page 2-A

REP G1=(3-19) 80-72 82-74

VAR G2=2-72 8-76/22-72 25-76/37-72 39-76/52-72 49-76/71-72 62-76

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 83

STEREO ATTRIBUTES: NONE

L5 855 SEA FILE=REGISTRY SSS FUL L2

L6 STR



REP G1=(3-19) 80-72 82-74

VAR G2=129-72 131-76/132-72 135-76/137-72 141-76

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 70

STEREO ATTRIBUTES: NONE

L8 43 SEA FILE=REGISTRY SSS FUL L6

L9 898 SEA FILE=REGISTRY ABB=ON PLU=ON L5 OR L8

L22 24999 SEA FILE=HCAPLUS ABB=ON PLU=ON PEPTIDES, PREPARATION/CT

L24 81 SEA FILE=HCAPLUS ABB=ON PLU=ON L9(L)PREP/RL AND L22

L25 8511 SEA FILE=HCAPLUS ABB=ON PLU=ON SOLID PHASE SYNTHESIS+NT/CT

L26 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L25

=> d l26 ibib abs hitstr 1-13

L26 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:1002705 HCAPLUS

DOCUMENT NUMBER: 140:199732

TITLE: Synthesis, conformation, and immunosuppressive activity of CLX and its analogs

AUTHOR(S): Ruchala, P.; Picur, B.; Lisowski, M.; Cierpicki, T.; Wieczorek, Z.; Siemion, I. Z.

CORPORATE SOURCE: Faculty of Chemistry, University of Wroclaw, Wroclaw, 50-383, Pol.

SOURCE: Biopolymers (2003), 70(4), 497-511

CODEN: BIPMAA; ISSN: 0006-3525

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The CLX peptide isolated from flax seed has a sequence cyclo-(PPFFILLX), where X is a nonproteinaceous amino acid residue, (2S,4R) 4-amine-N-methylproline (Picur at al., 1998). The structure of X strongly suggests that this natural amino acid plays a role of the dipeptide moiety with a nonplanar cis peptidomimetic bond. The X residue contains two asym. carbons and thus can appear in four configurations: (2S,4R), (2S,4S), (2R,4S), and (2R,4R). All four diastereoisomers of X were synthesized and characterized as trifluoroacetates of 4-phthalimido-N-methylproline benzylamides. Their full physicochem. characteristics are presented in this article. The synthesis of linear and cyclic analogs of CLX containing all four possible diastereoisomers of X was performed. Addnl., analogs with γ -aminobutyric acid (GABA) and glycyl-N-methyl-glycine dipeptide [G(Me)G] substituted for X were synthesized. The obtained peptides were purified using HPLC, examined by ESI/MS, and then studied by CD spectroscopy. They were also tested for immunosuppressive activity (PFC in vitro). All of them revealed diverse immunosuppressive activity, however, lower than that of cyclolinopeptide A (CLA) (Wieczorek at al., 1988). The structure of CLX with (2S,4R) 4-amino-N-methylproline was determined by 2-D NMR methods. All amide bonds are in the trans configuration. The cis peptidomimetic group δ -CH₂-N(CH₃)- is exposed to the outside of the CLX mol. The peptide contains two loops similar to β -turns of type IV (Chou at al., 1977) and has the extended shape flanked by F3 and L7 residues with significant side chain flexibility.

IT 660838-23-3P


RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**
(synthesis, conformation, and immunosuppressive activity of CLX-peptide and its analogs)

RN 660838-23-3 HCAPLUS


CN Cyclo(glycyl-N-methylglycyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-isoleucyl-L-leucyl-L-leucyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:534207 HCAPLUS

DOCUMENT NUMBER: 139:350928

TITLE: A family of macrocyclic antibiotics with a mixed peptide-peptoid β -hairpin backbone conformation
 AUTHOR(S): Shankaramma, Sasalu C.; Moehle, Kerstin; James, Sonya; Vrijbloed, Jan W.; Obrecht, Daniel; Robinson, John A.
 CORPORATE SOURCE: Institute of Organic Chemistry, University of Zurich, Zurich, 8057, Switz.

SOURCE: Chemical Communications (Cambridge, United Kingdom) (2003), (15), 1842-1843

CODEN: CHCOFS; ISSN: 1359-7345

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Macrocyclic peptidomimetics having a mixed peptide-peptoid backbone have been synthesized and shown to possess antibiotic activity against Gram-pos. and -neg. bacteria with a low hemolytic activity against human erythrocytes; one is shown to adopt a regular β -hairpin conformation by NMR in aqueous solution

IT **619297-77-7P 619297-78-8P**

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)** (solid-phase synthesis and biol. activity of macrocyclic peptide antibiotics with β -hairpin backbone conformation)


RN 619297-77-7 HCAPLUS

CN Cyclo[L-arginyl-L-leucyl-L-lysyl-L-lysyl-N-(4-aminobutyl)glycyl-L-arginyl-L-tryptophyl-L-lysyl-L-tyrosyl-L-arginyl-L-valyl-D-prolyl-L-prolyl-L-leucyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 1-B



PAGE 2-A




RN 619297-78-8 HCAPLUS

CN Cyclo[L-arginyl-L-leucyl-N-(4-aminobutyl)glycyl-L-lysyl-N-(4-aminobutyl)glycyl-L-arginyl-L-tryptophyl-L-lysyl-L-tyrosyl-L-arginyl-L-valyl-D-prolyl-L-prolyl-L-leucyl] (9CI) (CA INDEX NAME)




Absolute stereochemistry.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:509785 HCAPLUS
 DOCUMENT NUMBER: 140:164189
 TITLE: Cyclolinopeptide A analogues containing
 N-benzylglycine as a peptoid building block
 AUTHOR(S): Leplawy, Mirosław T.; Zubrzak, Paweł; Olejniczak,
 Bogdan; Paneth, Piotr; Smoluch, Marek; Silberring,
 Jerzy; Kowalski, Marek L.; Szkudlinska, Barbara;
 Grochulska, Ewa; Zabrocki, Janusz
 CORPORATE SOURCE: Institute of Organic Chemistry, Technical University,
 Łódź, 90-924, Pol.
 SOURCE: Peptides 2000, Proceedings of the European Peptide
 Symposium, 26th, Montpellier, France, Sept. 10-15,
 2000 (2001), Meeting Date 2000, 859-860. Editor(s):

Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK:
Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE:

Conference

LANGUAGE:

English

AB A symposium report. Linear and cyclic cyclolinopeptide A analogs containing benzylglycine in positions 8 and 9 were synthesized by SPPS technique, followed by cyclization. Four compds. were tested for immunosuppressive activity. Conformational search for studied peptides was carried out using random variation of four dihedral angles using MM+ and Amber 6 force fields.

IT 33302-55-5DP, Cyclolinopeptide A, analogs 655251-39-1P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**


(solid phase synthesis of linear and cyclic cyclolinopeptide A analogs, their immunosuppressive activity and conformation)

RN 33302-55-5 HCAPLUS


CN Cyclo(L-isoleucyl-L-isoleucyl-L-leucyl-L-valyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-leucyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 655251-39-1 HCAPLUS


CN Cyclo[N-(phenylmethyl)glycyl-N-(phenylmethyl)glycyl-L-leucyl-L-isoleucyl-L-isoleucyl-L-leucyl-L-valyl-L-prolyl-L-prolyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 655251-38-0P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);


BIOL (Biological study); **PREP (Preparation)**(solid phase synthesis of linear and cyclic cyclolipopeptide A analogs,
their immunosuppressive activity and conformation)

RN 655251-38-0 HCAPLUS


CN Cyclo[N-(phenylmethyl)glycyl-L-phenylalanyl-L-leucyl-L-isoleucyl-L-
isoleucyl-L-leucyl-L-valyl-L-prolyl-L-prolyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:509768 HCAPLUS

DOCUMENT NUMBER: 140:164184

TITLE: Mimetics of dipeptide moiety with nonplanar cis-amide bond

AUTHOR(S): Krajewski, Krzysztof; Ciunik, Zbigniew; Siemion, Ignacy Z.

CORPORATE SOURCE: Faculty of Chemistry, Wroclaw University, Wroclaw, 50-383, Pol.

SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 825-826. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A symposium report. Stereoisomers of 4-amino-3-hydroxy-1-cyclohexane carboxylic acid and 4-amino-3-oxo-1-cyclohexane carboxylic acids were designed as new peptidomimetics using for the synthesis of analogs of cyclinopeptide A [c-(Phe-Phe-Leu-Ile-Ile-Leu-Val-Pro-Pro)]. The analogs of CLA were synthesized by coupling of prepared peptide mimics with hexapeptide on the solid phase using Boc (Boc = tert-butoxycarbonyl) strategy. All of the analogs possess immunosuppressive activity but lower than the activity of cyclinopeptide A.

IT 33302-55-5DP, analogs

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent)


(solid phase synthesis of cyclinopeptide A analogs containing aminohydroxycyclohexane and aminooxocyclohexane carboxylic acids as peptidomimetics with immunosuppressive activity)

RN 33302-55-5 HCAPLUS


CN Cyclo(L-isoleucyl-L-isoleucyl-L-leucyl-L-valyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-leucyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:754415 HCAPLUS

DOCUMENT NUMBER: 137:263304

TITLE: Synthesis of peptides and medical uses of
intracellular communication facilitating compoundsINVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier,
Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye;
Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik;
Martins, James B.

PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.

SOURCE: PCT Int. Appl., 233 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077017	A2	20021003	WO 2002-US5773	20020222
WO 2002077017	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2001062775	A2	20010830	WO 2001-DK127	20010222
WO 2001062775	A3	20020131		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003092609	A1	20030515	US 2001-792286	20010222
EP 1370276	A2	20031217	EP 2002-723240	20020222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003003641	A	20031020	NO 2003-3641	20030815
PRIORITY APPLN. INFO.:				
			US 2001-792286	A 20010222
			WO 2001-DK127	A 20010222
			US 2001-314470P	P 20010823
			DK 2000-288	A 20000223
			DK 2000-738	A 20000504
			US 2000-251659P	P 20001206
			WO 2002-US5773	W 20020222

OTHER SOURCE(S): MARPAT 137:263304

AB The invention relates to novel peptides, including novel antiarrhythmic peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the

use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. The invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH₂ (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PI-turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IT 355151-13-2P 355151-14-3P 355151-45-0P

355151-46-1P 355151-47-2P 463362-34-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**;

USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 355151-13-2 HCAPLUS


CN Cyclo[L-alanylglycyl-L-asparaginyl-L-tyrosyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-14-3 HCAPLUS

CN Cyclo[L-alanyl-L-asparaginyl-L-tyrosyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355151-45-0 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-46-1 HCAPLUS
CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-47-2 HCAPLUS
CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 463362-34-7 HCAPLUS
CN Cyclo[L-alanylglycyl-L-asparaginyL-3,5-diiodo-L-tyrosyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L26 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:692585 HCAPLUS

DOCUMENT NUMBER: 138:354229

TITLE: Cyclic analogues of the insect antimicrobial peptides drosocin and apidaecin

AUTHOR(S): Gobbo, Marina; Benincasa, Monica; Biondi, Laura; Filira, Fernando; Gennaro, Renato; Rocchi, Raniero

CORPORATE SOURCE: Centro di Studio sui Biopolimeri del C. N. R., Dipartimento di Chimica Organica, Universita di Padova, Padua, I-35131, Italy

SOURCE: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 776-777. Editor(s): Lebl, Michal; Houghten, Richard A. American Peptide Society: San Diego, Calif.

CODEN: 69DBAL; ISBN: 0-9715560-0-8

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A symposium report. Head-to-tail cyclic analogs of drosocin and apidaecin Ib were synthesized on solid phase and cyclized in solution and their antibacterial activity were compared with those of the unmodified linear peptides.

IT **518036-27-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**

(preparation of cyclic analogs of insect antimicrobial peptides drosocin and apidaecin by SPSS and cyclization)

RN 518036-27-6 HCAPLUS

CN Cyclo(L-arginyl-L-isoleucylglycyl-L-asparaginyL-L-asparaginyL-L-arginyl-L-prolyl-L-valyl-L-tyrosyl-L-isoleucyl-L-prolyl-L-glutaminyL-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-histidyl-L-prolyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:692514 HCAPLUS


DOCUMENT NUMBER: 138:354220

TITLE: Linear and cyclic Thr6-bradykinin analogs containing N-benzylglycine as a replacement for residues Phe5 and Phe8


AUTHOR(S): Gobbo, Marina; Biondi, Laura; Filira, Fernando;
Scolaro, Barbara; Rocchi, Raniero; Piek, Tom
CORPORATE SOURCE: Department of Organic Chemistry, Biopolymer Research
Centre, C.N.R., University of Padova, Padua, 35131,
Italy
SOURCE: Peptides: The Wave of the Future, Proceedings of the
Second International and the Seventeenth American
Peptide Symposium, San Diego, CA, United States, June
9-14, 2001 (2001), 628-629. Editor(s): Lebl, Michal;
Houghten, Richard A. American Peptide Society: San
Diego, Calif.
CODEN: 69DBAL; ISBN: 0-9715560-0-8
DOCUMENT TYPE: Conference
LANGUAGE: English
AB A symposium report. The solid phase synthesis and some preliminary
pharmacol. expts. and structural investigations of new linear and cyclic
Thr6-BK analogs, in which either one or both the Phe residues in the
peptide sequence have been substituted by N-benzylglycine, are presented.
IT **407624-49-1P 407624-50-4P 407624-51-5P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); BIOL (Biological study); **PREP (Preparation)**
(solid phase synthesis, structure, and pharmacol. expts. of
Thr6-bradykinin analogs containing benzylglycine as replacement for
residues Phe5 and Phe8)
RN 407624-49-1 HCAPLUS
CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolylglycyl-N-(phenylmethyl)glycyl-L-
threonyl-L-prolyl-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 407624-50-4 HCAPLUS


CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolyl]glycyl-L-phenylalanyl-L-threonyl-L-prolyl-N-(phenylmethyl)glycyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 407624-51-5 HCAPLUS


CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolyl]glycyl-L-threonyl-L-prolyl-N-(phenylmethyl)glycyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:156860 HCAPLUS

DOCUMENT NUMBER: 137:295219

TITLE: Search for new synthetic immunosuppressants II.

Tetrazole analogues of hymenistatin I

AUTHOR(S): Zubrzak, Pawel; Kociolek, Karol; Smoluch, Marek; Silberring, Jerzy; Kowalski, Marek L.; Szkudlinska, Barbara; Zabrocki, Janusz

CORPORATE SOURCE: Institute of Organic Chemistry, Technical University of Lodz, Lodz, 90-543, Pol.

SOURCE: Acta Biochimica Polonica (2001), 48(4), 1151-1154

CODEN: ABPLAF; ISSN: 0001-527X

PUBLISHER: Polish Biochemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:295219

AB Linear and cyclic hymenistatin I (HS I) analogs with dipeptide segments Ile2-Pro3, Pro3-Pro4 and Val6-Pro7 replaced by their tetrazole analogs Ile2-ψ[CN4]-Ala3, Pro3-ψ[CN4]-Ala4 and Val6-ψ[CN4]-Ala7 were synthesized by the solid phase peptide synthesis method and cyclized with the TBTU and/or HATU reagent. The peptides are devoid of immunosuppressive activity as assayed by the lymphocyte proliferation test (LPT).

IT 129536-23-8DP, Hymenistatin I, tetrazole analogs

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**

(tetrazole analogs of hymenistatin I as new synthetic immunosuppressants)

RN 129536-23-8 HCAPLUS

CN Hymenistatin 1 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:33445 HCAPLUS

DOCUMENT NUMBER: 136:295071

TITLE: Synthesis, conformation and biological activity of linear and cyclic Thr6-bradykinin analogs containing N-benzylglycine in place of phenylalanine

AUTHOR(S): Biondi, L.; Filira, F.; Gobbo, M.; Sclararo, B.; Rocchi, R.; Galeazzi, R.; Orena, M.; Zeegers, A.; Piek, T.

CORPORATE SOURCE: Department of Organic Chemistry, Biopolymer Research Centre, CNR, University of Padova, Padua, I-35131, Italy

SOURCE: Journal of Peptide Science (2001), 7(12), 626-640
CODEN: JPSIEI; ISSN: 1075-2617

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Three linear Thr6-bradykinin analogs in which either one or both the two phenylalanine residues in the peptide sequence have been substituted by N-benzylglycine (BzlGly) and their head-to-tail cyclic analogs were synthesized and tested on an isolated rat duodenum preparation. The linear (BzlGly5,Thr6-BK, BzlGly8,Thr6-BK and BzlGly5,8,Thr6-BK) and the cyclic (cyclo BzlGly5,Thr6-BK, cyclo BzlGly8,Thr6-BK and cyclo BzlGly5,8,Thr6-BK) peptoid-like analogs were characterized by amino acid anal., optical rotation, anal. HPLC and MALDI-TOF mass spectroscopy. The conformational features of both the linear and cyclic derivs. were investigated by FT-IR and CD measurements. Preliminary mol. mechanics calcns. were also performed on some synthetic peptides. Pharmacol. screening using the relaxation of the isolated rat duodenum preparation showed that incorporation of N-benzylglycine at positions 5 and/or 8 in the linear Thr6-BK causes a substantial decrease in potency. Comparable incorporation in cyclo Thr6-BK, at position 8, or 5 and 8, resulted in nearly inactive analogs. However, cyclo BzlGly5,Thr6-BK showed a potency which is of the same order of magnitude as for cyclo-BK and cyclo Thr6-BK.

IT 407624-56-0P

RL: BYP (Byproduct); PREP (Preparation)
(preparation, conformation and biol. activity of linear and cyclic Thr6-bradykinin analogs containing benzylglycine)

RN 407624-56-0 HCAPLUS

CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-threonyl-L-prolyl-N-(phenylmethyl)glycyl-L-arginyl-L-arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-threonyl-L-prolyl-N-(phenylmethyl)glycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 407624-49-1P


RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation, conformation and biol. activity of linear and cyclic Thr6-bradykinin analogs containing benzylglycine)

RN 407624-49-1 HCAPLUS


CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolylglycyl-N-(phenylmethyl)glycyl-L-threonyl-L-prolyl-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 407624-50-4P 407624-51-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**
 (preparation, conformation and biol. activity of linear and cyclic
 Thr6-bradykinin analogs containing benzylglycine)

RN 407624-50-4 HCAPLUS



CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolyl-glycyl-L-phenylalanyl-L-threonyl-L-prolyl-N-(phenylmethyl)glycyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Mondesi 10/070,217

PAGE 1-A


09/01/2004




RN 407624-51-5 HCAPLUS
CN Cyclo[L-arginyl-L-arginyl-L-prolyl-L-prolyl-L-threonyl-L-
threonyl-L-prolyl-N-(phenylmethyl)glycyl] (9CI) (CA INDEX NAME)
Absolute stereochemistry.

Searched by Paul Schulwitz 571-272-2527

PAGE 1-A



PAGE 1-B




IT 407624-57-1P 407624-58-2P 407624-59-3P

RL: RCT (Reactant); SPN (Synthetic preparation); **PREP**
(Preparation); RACT (Reactant or reagent)(preparation, conformation and biol. activity of linear and cyclic
Thr6-bradykinin analogs containing benzylglycine)


RN 407624-57-1 HCAPLUS

CN Cyclo[glycyl-N-(phenylmethyl)glycyl-O-(1,1-dimethylethyl)-L-threonyl-L-prolyl-L-phenylalanyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-L-prolyl-L-prolyl] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 407624-58-2 HCAPLUS


CN Cyclo[N-(phenylmethyl)glycyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-O-(1,1-dimethylethyl)-L-threonyl-L-prolyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 407624-59-3 HCAPLUS
 CN Cyclo[glycyl-N-(phenylmethyl)glycyl-O-(1,1-dimethylethyl)-L-threonyl-L-prolyl-N-(phenylmethyl)glycyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-L-prolyl-L-prolyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:772915 HCAPLUS
 DOCUMENT NUMBER: 136:70074
 TITLE: The Development and Application of a Novel Safety-Catch Linker for Boc-Based Assembly of Libraries of Cyclic Peptides
 AUTHOR(S): Bourne, Gregory T.; Golding, Simon W.; McGeary, Ross P.; Meutermans, Wim D. F.; Jones, Alun; Marshall, Garland R.; Alewood, Paul F.; Smythe, Mark L.
 CORPORATE SOURCE: Centre for Drug Design and Development Institute for Molecular Bioscience, The University of Queensland, St. Lucia Brisbane, 4072, Australia
 SOURCE: Journal of Organic Chemistry (2001), 66(23), 7706-7713
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal

LANGUAGE: English

AB' Cyclic peptides are appealing targets in the drug-discovery process. Unfortunately, there currently exist no robust solid-phase strategies that allow the synthesis of large arrays of discrete cyclic peptides. Existing strategies are complicated, when synthesizing large libraries, by the extensive workup that is required to extract the cyclic product from the deprotection/cleavage mixture. To overcome this, we have developed a new safety-catch linker. The safety-catch concept described here involves the use of a protected catechol derivative in which one of the hydroxyls is masked with a benzyl group during peptide synthesis, thus making the linker deactivated to aminolysis. This masked derivative of the linker allows Boc solid-phase peptide assembly of the linear precursor. Prior to cyclization, the linker is activated and the linear peptide is deprotected using conditions commonly employed (TFMSA), resulting in deprotected peptide attached to the activated form of the linker. Scavengers and deprotection adducts are removed by simple washing and filtration. Upon neutralization of the N-terminal amine, cyclization with concomitant cleavage from the resin yields the cyclic peptide in DMF solution. Workup is simple solvent removal. To exemplify this strategy, several cyclic peptides were synthesized targeted toward the somatostatin and integrin receptors. From this initial study and to show the strength of this method, we were able to synthesize a cyclic-peptide library containing over 400 members. This linker technol. provides a new solid-phase avenue to access large arrays of cyclic peptides.

IT 385427-24-7P 385427-28-1P 385427-44-1P

385427-50-9P 385427-54-3P 385427-65-6P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of a library of cyclic peptides on solid-phase by using a novel safety-catch linker)

RN 385427-24-7 HCAPLUS


CN Cyclo(L-isoleucyl-D-tryptophyl-L-prolyl-D-prolyl-L-phenylalanyl-L-tyrosyl)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 385427-28-1 HCAPLUS


CN Cyclo(L-α-aspartyl-L-seryl-L-prolyl-D-prolylglycyl-L-tyrosyl) (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 385427-44-1 HCAPLUS


CN Cyclo(L-alanyl-L-arginyl-L-α-glutamyl-D-prolyl-L-prolyl-L-tryptophyl) (9CI) (CA INDEX NAME)



RN 385427-50-9 HCAPLUS

CN Cyclo(L-α-aspartyl-L-tryptophyl-L-seryl-L-prolyl-D-prolylglycyl)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385427-54-3 HCAPLUS


CN Cyclo(L-arginyl-D-prolyl-L-prolyl-L-phenylalanyl-L-tryptophyl-L-tyrosyl)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 385427-65-6 HCAPLUS

CN Cyclo(L-arginyl-L-prolyl-D-prolylglycyl-L- α -aspartyl-L-isoleucyl)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:651017 HCAPLUS

DOCUMENT NUMBER: 136:54018

TITLE: Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase

AUTHOR(S): Long, Y.-Q.; Lee, S.-L.; Lin, C.-Y.; Enyedy, I. J.; Wang, S.; Li, P.; Dickson, R. B.; Roller, P. P.

CORPORATE SOURCE: Laboratory of Medicinal Chemistry, FCRDC, National Cancer Institute, NIH, Frederick, MD, 21702, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(18), 2515-2519

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We report here the synthesis of a 14-amino acid long bicyclic peptide, previously isolated from sunflower seeds. This peptide, termed sunflower trypsin inhibitor (SFTI-1), is one of the most potent naturally occurring small-mol. trypsin inhibitors. In addition to inhibiting trypsin, the synthetic SFTI-1 is also a very potent inhibitor, with a K_i of 0.92 nM, of the recently identified epithelial serine protease, termed 'matriptase'.

IT **245080-24-4P**, SFTI-1

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**

(preparation and evaluation of sunflower derived bicyclic peptide trypsin selective inhibitor as inhibitor of type II transmembrane serine protease matriptase)

RN 245080-24-4 HCAPLUS

CN Cyclo(L-arginyl-L-cysteinyl-L-threonyl-L-lysyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-isoleucyl-L-cysteinyl-L-phenylalanyl-L-prolyl-L- α -aspartylglycyl), cyclic (2 \rightarrow 10)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:168018 HCAPLUS
DOCUMENT NUMBER: 134:208139
TITLE: Synthesis of template-fixed β -hairpin loop
mimetics
INVENTOR(S): Robinson, John A.; Obrecht, Daniel
PATENT ASSIGNEE(S): Polyphor A.-G., Switz.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016161	A1	20010308	WO 1999-EP6369	19990830
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
BR 9917475	A	20020514	BR 1999-17475	19990830
EP 1214336	A1	20020619	EP 1999-946064	19990830
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
JP 2004511424	T2	20040415	JP 2001-519722	19990830
PRIORITY APPLN. INFO.:			WO 1999-EP6369	A 19990830
OTHER SOURCE(S):			CASREACT 134:208139; MARPAT 134:208139	

GI




AB Template-fixed β -hairpin loop mimetics comprising a template corresponding to one of eight structures (e.g., I, R1 is H or a protected amino group and II, R2 is carboxymethyl or its esters) and a template-fixed chain of 4 to 20 α -amino acid residues which, if their α -C atom is asym., have L-configuration, can be manufactured by a novel process which is based on a mixed solid- and solution phase synthetic strategy. If desired, this process can be modified to give the enantiomers of these template-fixed β -hairpin loop mimetics. Twelve reaction schemes are given which illustrate the preparation of the template-incorporating compds. The synthesis of the linear peptides prior to cyclization and deprotection is illustrated as follows: the first amino acid Fmoc-Arg(Pmc)-OH (1 equiv) (Fmoc = 9-fluorenylmethoxycarbonylallyloxy carbonyl; Pmc = 2,2,5,7,8-pentamethylchroman-6-sulfonyl) was linked to 2-chlorotrityl chloride resin (Polyphor, 1.25 mmol/g) with 3 equiv DIEA in DCM overnight; the linear peptides were assembled using standard Fmoc chemical, 4 equiv each of amino acids and of the template (or, if appropriate, of Fmoc-L-Pro-OH and of Fmoc-D-Pro-OH), 4 equiv each of HBTU and HOBt and 6 equivalent of DIEA in DMF being used and the coupling time being 1.5-2 h; and the protected linear peptides were cleaved from the resin with 1% TFA in DCM (4 x 10 min) and neutralized with pyridine (1 equiv), then the solvent was evaporated

IT 329076-98-4P 329076-99-5P 329077-00-1P
329077-01-2P 329077-02-3P 329077-03-4P
329077-04-5P 329077-05-6P 329077-06-7P
329077-07-8P 329077-08-9P 329077-09-0P
329077-10-3P 329077-11-4P 329077-12-5P
329077-13-6P 329077-14-7P 329077-15-8P
329077-16-9P 329077-17-0P 329077-18-1P
329077-19-2P 329077-20-5P 329077-21-6P
329077-22-7P 329077-23-8P 329077-24-9P
329077-25-0P 329077-26-1P 329077-27-2P
329077-28-3P 329077-29-4P 329077-30-7P
329077-31-8P 329077-32-9P 329077-33-0P
329077-34-1P 329077-35-2P 329077-36-3P
329077-37-4P
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(synthesis of template-fixed β -hairpin loop mimetics from resin-bound arginine derivative)

RN 329076-98-4 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-prolyl-L-isoleucyl-D-prolyl-L-prolyl-L- α -glutamyl-L-isoleucyl-L-valyl) (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—CO₂H

PAGE 2-A



RN 329076-99-5 HCAPLUS

CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-tyrosyl-L-isoleucyl-D-prolyl-L-prolyl-L- α -glutamyl-L-tyrosyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-00-1 HCAPLUS

CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-tryptophyl-L-isoleucyl-D-prolyl-L-prolyl-L- α -glutamyl-L-tryptophyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-01-2 HCAPLUS

CN Cyclo(L-alanyl-L-isoleucyl-D-prolyl-L-prolyl-L- α -glutamyl-L-alanyl-L-valyl-L-arginyl-L-lysyl-L-lysyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-02-3 HCAPLUS

CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-seryl-L-isoleucyl-D-prolyl-L-prolyl-L- α -glutamyl-L-seryl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-03-4 HCAPLUS


CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-lysyl-L-isoleucyl-D-prolyl-L-prolyl-L- α -glutamyl-L-lysyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 329077-04-5 HCAPLUS

CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-prolyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-isoleucyl-L-valyl) (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 329077-05-6 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-tyrosyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-tyrosyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-06-7 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-tryptophyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-tryptophyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-07-8 HCAPLUS
CN Cyclo(L-alanyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-alanyl-L-valyl-L-arginyl-L-lysyl-L-lysyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-08-9 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-seryl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-seryl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-09-0 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-lysyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 329077-10-3 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-prolyl-L-tryptophyl-D-prolyl-L-prolyl-L-tryptophyl-L-isoleucyl-L-valyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/01/2004

Mondesi 10/070,217

PAGE 1-A




PAGE 1-B



Page 37

Searched by Paul Schulwitz 571-272-2527

PAGE 2-A



RN 329077-11-4 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-tyrosyl-L-tryptophyl-D-prolyl-L-prolyl-L-tryptophyl-L-tyrosyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-12-5 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-tryptophyl-L-tryptophyl-D-prolyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-13-6 HCAPLUS
CN Cyclo(L-alanyl-L-tryptophyl-D-prolyl-L-prolyl-L-tryptophyl-L-alanyl-L-valyl-L-arginyl-L-lysyl-L-lysyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-14-7 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-seryl-L-tryptophyl-D-prolyl-L-prolyl-L-tryptophyl-L-seryl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 329077-15-8 HCAPLUS
CN Cyclo(L-arginyl-L-lysyl-L-lysyl-L-lysyl-L-tryptophyl-D-prolyl-L-prolyl-L-tryptophyl-L-lysyl-L-valyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 329077-16-9 HCAPLUS
CN Cyclo(L-alanyl-L-isoleucyl-L-valyl-L-arginyl-L-lysyl-L-lysyl-L-prolyl-L-alanyl-D-prolyl-L-prolyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 329077-17-0 HCAPLUS

CN Cyclo(L-alanyl-D-prolyl-L-prolyl-L-alanyl-L-tyrosyl-L-valyl-L-arginyl-L-lysyl-L-lysyl-L-tyrosyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-18-1 HCAPLUS

CN Cyclo(L-alanyl-D-prolyl-L-prolyl-L-alanyl-L-tryptophyl-L-valyl-L-arginyl-L-lysyl-L-lysyl-L-tryptophyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-19-2 HCAPLUS

CN Cyclo(L-alanyl-L-alanyl-D-prolyl-L-prolyl-L-alanyl-L-alanyl-L-valyl-L-arginyl-L-lysyl-L-lysyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-20-5 HCAPLUS

CN Cyclo(L-alanyl-D-prolyl-L-prolyl-L-alanyl-L-seryl-L-valyl-L-arginyl-L-lysyl-L-lysyl-L-seryl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-21-6 HCAPLUS

CN Cyclo(L-alanyl-L-lysyl-L-valyl-L-arginyl-L-lysyl-L-lysyl-L-lysyl-L-alanyl-D-prolyl-L-prolyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-22-7 HCAPLUS

CN Cyclo(L-alanyl-L-arginyl-L-arginyl-L-alanyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-23-8 HCAPLUS

CN Cyclo(L-alanyl-L-arginyl-L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-24-9 HCAPLUS

CN Cyclo(L-alanyl-L-arginyl-L-arginyl-L-alanyl-L-lysyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-25-0 HCAPLUS

CN Cyclo(L-alanyl-L-arginyl-L-arginyl-L-alanyl-L-lysyl-L-tryptophyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl) (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-26-1 HCAPLUS


CN Cyclo(L-alanyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl-L-tyrosyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A





RN 329077-27-2 HCAPLUS
 CN Cyclo(L-alanyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl-L-lysyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 329077-28-3 HCAPLUS



CN Cyclo(L-alanyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl-L-tyrosyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 329077-29-4 HCAPLUS
 CN Cyclo(L-alanyl-L-arginyl-L-arginyl-L-alanyl-L- α -glutamyl-L-phenylalanyl-L-alanyl-L-phenylalanyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L- α -glutamyl-L-tyrosyl-L-alanyl-L-tyrosyl-L-lysyl) (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 2-C




RN 329077-30-7 HCAPLUS

CN Cyclo(L-alanyl-L-arginyl-L-arginyl-L-alanyl-L-α-glutamyl-L-tyrosyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-L-tyrosyl-L-α-glutamyl-L-tyrosyl-L-alanyl-L-lysyl-L-lysyl) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


PAGE 1-C



PAGE 2-B




PAGE 2-C




RN 329077-31-8 HCAPLUS
 CN Cyclo[L-alanyl-L-arginyl-L-arginyl-L-alanyl-L-lysyl-L-tyrosyl-5-(aminomethyl)-3,6-dimethoxy-9,9-dimethyl-9H-xanthene-4-acetyl-L-tyrosyl-L-

1 4

PAGE 1-A



PAGE 2-A




RN 329077-33-0 HCAPLUS

CN Cyclo[L-alanyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-tyrosyl-5-(aminomethyl)-3,6-dimethoxy-9,9-dimethyl-9H-xanthene-4-acetyl-L-tyrosyl-L- α -glutamyl-L-lysyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

O


PAGE 2-A




PAGE 2-B




PAGE 3-A



PAGE 3-B




PAGE 4-A



RN 329077-34-1 HCAPLUS
 CN Cyclo[(3S,7S,8aR)-7-amino-8a-(carboxymethyl)octahydro-1,4-dioxopyrrolo[1,2-a]pyrazine-3-acetyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-arginyl-L-lysyl-L-tryptophyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B


OH

RN 329077-35-2 HCAPLUS
 CN Cyclo[L-alanyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-phenylalanyl-5-(aminomethyl)-3,6-dimethoxy-9,9-dimethyl-9H-xanthene-4-acetyl-L-tyrosyl-L- α -glutamyl-L-phenylalanyl] (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



PAGE 2-B




O



PAGE 3-A

PAGE 3-B



RN 329077-36-3 HCAPLUS

CN Cyclo[L-alanyl-L-tyrosyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-tyrosyl-L-alanyl-L-tyrosyl-L-lysyl-L-tyrosyl-(3S,7S,8aR)-7-amino-8a-(carboxymethyl)octahydro-1,4-dioxopyrrolo[1,2-a]pyrazine-3-acetyl-L-tyrosyl-L- α -glutamyl-L-tyrosyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 329077-37-4 HCAPLUS


CN Cyclo[L-alanyl-L-lysyl-L-arginyl-L-arginyl-L- α -glutamyl-L-alanyl-L-

lysyl-L-lysyl-L-tyrosyl-5-(aminomethyl)-3,6-dimethoxy-9,9-dimethyl-9H-xanthene-4-acetyl-L-tyrosyl-L- α -glutamyl-L-tyrosyl] (9CI) (CA INDEX NAME)


PAGE 1-B

Me Me


PAGE 2-A




PAGE 2-B




PAGE 3-A



PAGE 3-B



PAGE 4-A




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1977:140451 HCAPLUS
 DOCUMENT NUMBER: 86:140451
 TITLE: Monitoring of solid-phase peptide synthesis by potentiometric titration of samples
 AUTHOR(S): Schou, Ole
 CORPORATE SOURCE: Dan. Inst. Protein Chem., Hoersholm, Den.
 SOURCE: Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1976), B30(10), 991-3
 CODEN: ACBOCV; ISSN: 0302-4369
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The solid-phase synthesis of Me3CO2C-Phe-Pro-Pro-Phe-Phe-Val-Pro-Pro-Ala-Phe-resin (I) was monitored by withdrawing a sample after each coupling and potentiometrically titrating with HClO4. A quant. determination of the yields in the single steps during the synthesis was obtained. I was cleaved with HBr-CF3CO2H and cyclized to give antamanide.
 IT 16898-32-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by solid-phase method)
 RN 16898-32-1 HCAPLUS


CN Antamanide (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A

PAGE 2-B

